Report on the developments of the National Immunisation Programme: national immunisation coverage increased slightly for the first time in five years National immunisation coverage has increased for the first time in five years, for almost all vaccinations. For children born in 2017, vaccination coverage against mumps, measles and rubella (MMR) increased by 0.7% to 93.6%.
Spread of tick-borne encephalitis virus in the Netherlands Every year about 1.5 million ticks bite someone in the Netherlands, especially between March and October. Most people will not get sick of that.
A pregnant woman can protect her baby against whooping cough with 22-week vaccination From 16 December 2019, pregnant women in the Netherlands will be offered the 22-week vaccination. With this vaccination, a pregnant woman protects her child and herself against whooping cough.
Can you solve a medical mystery? During World Antibiotic Awareness Week 2019, RIVM has set up an escape room in one of busiest shopping malls in the Netherlands.
Mild 2018-2019 influenza epidemic The annual influenza epidemic in the winter of 2018-2019 was less severe than the year before. Approximately 400,000 people have had the flu.
Discussion regarding health-based guidance value of PFOA The European Food Safety Authority (EFSA) has published a provisional health-based guidance value for perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA).
Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.
New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
Influenza-like Illness Incidence Is Not Reduced by Influenza Vaccination Influenza vaccination reduces the number of influenza virus infections but not the overall number of illness.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.